ReviewWorldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014
Introduction
Autoimmune systemic diseases (AISDs) are a heterogeneous group of conditions characterized by an immune dysregulation resulting in inflammation and multi-organ involvements [1]. The prevalence of autoimmune diseases is currently estimated to range from 4 to 5% of the general population in developed countries [2,3], and is expected to increase globally [4]. The care of patients with AISDs is often challenging [5], and despite recent advances in immunosuppressive treatments [[6], [7], [8]], the burden of AISDs remains high [[9], [10], [11]]. World-wide differences in AISDs mortality are largely multifactorial and involve the role of different genetic backgrounds [12], socio-economic level and access to care [13], the variable efficacy of treatments [14], their side-effects, as well as the burden of comorbidities [15,16]. Also, methodological differences in mortality assessment methods may limit inter-country comparability. As of today, AISD mortality has essentially been studied in limited geographical areas such as at a given institution-, region- or more rarely country-level, mostly using registries or cohorts [10,[17], [18], [19]]. While these approaches have provided important data, inter-country comparisons from different sources are limited and a global overview of AISDs mortality is currently lacking. Noteworthy, worldwide data on AISD mortality are of major interest to policymakers as well as to physicians involved in the care of these rare diseases.
Here, we used publicly available data from the World Health Organization (WHO), to analyze worldwide temporal trends of mortality data for six AISDs, namely Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), Sjögren's Syndrome (SS), Idiopathic Inflammatory Myopathies (IIM), Mixed Connective Tissue Disease (MCTD) and Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis (AAV).
Section snippets
Data sources & handling
Data of cause-specific deaths were retrieved from the publicly available WHO mortality database (http://www.who.int/healthinfo/mortality_data/). Retrieved data included the number of cause-specific deaths, age category for each country, year and gender. Population data according to sex and age were retrieved from the United Nations World prospects database (https://population.un.org/wpp/Download/Standard/Population/). For geographical analysis, the countries were grouped as follows: Europe,
Systemic lupus erythematosus
For the year 2014, 6418 SLE-related deaths occurred in 84 countries (Fig. 1A & Suppl. Table 1), corresponding to 0.021% of all deaths and yielding a global ASMR of 2.68 (95%CI: 2.62–2.75) per million inhabitants. The ASMR was 4.53 (4.40–4.65) for women and 0.79 (0.73–0.84) for men. The ASMR ranged from 0.11 in Morocco to 27.1 deaths per million in Saint Lucia (Fig. 2 & Supplementary Table 1). For the year 2014, the ASMR of SLE in Europe (1.06 [95%CI: 0.98–1.13] deaths/million) was significantly
Discussion
In this study, we used world-wide data from the World Health Organization to analyze worldwide mortality data of 6 auto-immune and systemic conditions, namely SLE, SSc, SS, IIM, MCTD and AAV. One main strength of the study is the use of standardized mortality rates as a way to account for differences in the heterogenous age structure of the populations studied. Further, we were able to analyze temporal changes in all-cause disease-specific mortality data over a span of 14 years.
While not
Conclusions
Altogether, we used world-wide data from the World Health Organization to analyze detailed temporal trends of standardized all-cause disease-specific mortality rates for 6 major systemic auto-immune conditions. Our results reveal major differences in mortality between those 6 AISDs, and the generally better prognosis in Europe versus other geographical regions, including North America. Those results further highlight the impact of world-wide inequities and major gaps in access to care and
Disclosures
None.
Funding
None.
Acknowledgements
The authors wish to thank Ms. Thuong for her invaluable assistance in the handling of the manuscript. The study was performed based on publicly available WHO data. However, the WHO was not involved in this study which was performed independently by its authors.
References (24)
- et al.
Systemic rheumatic diseases: from biological agents to small molecules
Autoimmun Rev
(2019) - et al.
Updated assessment of the prevalence, spectrum and case definition of autoimmune disease
Autoimmun Rev
(2012) - et al.
Biotherapies in systemic lupus erythematosus: new targets
Joint Bone Spine
(2017) - et al.
The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials
Autoimmun Rev
(2018) - et al.
The pipeline of targeted therapies under clinical development for primary Sjögren’s syndrome: a systematic review of trials
Autoimmun Rev
(2019) - et al.
Optimizing conventional DMARD therapy for Sjögren’s syndrome
Autoimmun Rev
(2018) - et al.
Systemic lupus erythematosus and hypertension
Autoimmun Rev
(2019) - et al.
The burden of chronic kidney disease in systemic lupus erythematosus: a nationwide epidemiologic study
Autoimmun Rev
(2019) - et al.
Prevalence and incidence of systemic lupus erythematosus in France: a 2010 nation-wide population-based study
Autoimmun Rev
(2014) - et al.
Emerging role of air pollution in autoimmune diseases
Autoimmun Rev
(2019)
Cited by (75)
Autoimmune diseases mortality: Secular trends and causes
2024, Revue du Rhumatisme (Edition Francaise)Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019
2023, Autoimmunity ReviewsA population-based study on autoimmune disease
2023, The Lancet
- 1
Those authors contributed equally to this work